경도인지장애 시장 : 적응증별, 질환 유형별, 연령대별, 국가별, 지역별 - 산업 분석, 시장 규모, 시장 점유율, 예측(2024-2032년)

REPORT HIGHLIGHT

Mild Cognitive Impairment Market size was valued at USD 1,980.21 Million in 2023, expanding at a CAGR of 5.24% from 2024 to 2032.

Mild Cognitive Impairment (MCI) is a kind of disease characterized by noticeable changes in cognitive function that are greater than expected for a person's age but not severe enough to interfere significantly with daily life. People with MCI might experience difficulties with memory, language, thinking, or judgment that are noticeable to themselves or others.

Mild Cognitive Impairment Market- Market Dynamics

The growing older population and advancement in diagnostic methods are expected to propel market demand

The prevalence of MCI and other cognitive disorders increases as the population rises. The growing number of older fuels demand diagnostic tools, treatments, and management strategies. There is a greater awareness and understanding of MCI among healthcare providers and the public. Advances in diagnostic methods and increased educational efforts contribute to higher detection rates and subsequent demand for interventions.

Further, increased healthcare spending on cognitive health and related areas drives demand for MCI-related products and services. Governments and private sectors are investing in better care solutions for cognitive disorders. The rise of digital health technologies, such as cognitive training apps, telemedicine, and wearable devices, enhances the management and monitoring of MCI. Technology improves patient engagement and provides new avenues for treatment and research. The development of drugs aimed at managing symptoms or modifying the progression of MCI influences market dynamics. New therapeutic agents and clinical trials contribute to growth in the pharmaceutical sector.

Mild Cognitive Impairment Market- Key Insights

As per the analysis shared by our research analyst, the global market is estimated to grow annually at a CAGR of around 524% over the forecast period (2024-2032)

Based on Indication segmentation, the Alzheimer's disease (AD) segment was predicted to show maximum market share in the year 2023, owing to the increased prevalence of Alzheimer's disease.

Based on Disease Type segmentation, the amnestic segment was the leading Disease Type in 2023, due to high prevalence among older adults.

Based on Age Group segmentation, the geriatric segment was the leading Age Group in 2023, owing to the high need for treatment of Alzheimer's, vascular dementia, etc.

On the basis of region, North America was the leading revenue generator in 2023, mainly due to the high incidence of Alzheimer's disease.

Mild Cognitive Impairment Market- Segmentation Analysis:

The Global Mild Cognitive Impairment Market is segmented on the basis of Indication, Disease Type, Age Group, and Region.

The market is divided into five categories based on Indication: Alzheimer's Disease, Vascular Dementia, Lewy Body Dementia, Parkinson's Disease Dementia, and others. The Alzheimer's Disease Dementia segment dominates the market. Mild cognitive impairment is needed for dementia cure which is contributing to segment growth.

The market is divided into two categories based on Disease Type: amnestic MCI and non-amnestic MCI. The amnestic MCI segment is projected to hold the largest share of the market. Amnestic mild cognitive impairment indicates memory deficiency and is not so severe condition but is growing among old age people.

The market is divided into three categories based on Age Group: child, adult, and geriatric. The geriatric segment dominates the market and is expected to maintain its high dominance during the forecast period. Older age people suffering from Alzheimer's and having mild cognitive impairment issue are boosting segment demand.

Mild Cognitive Impairment Market- Geographical Insights

Geographically, this market is widespread in the regions of North America, Latin America, Europe, Asia Pacific, and the Middle East and Africa. North America dominates the Mild Cognitive Impairment market. The U.S. has a large and growing elderly population, contributing to a high prevalence of MCI. There is significant investment in research and development, along with advanced healthcare infrastructure that supports early diagnosis and treatment. In Asia, Japan has a high proportion of elderly individuals and is a leader in research and development related to cognitive impairments. The country has well-established healthcare services for managing MCI.

Mild Cognitive Impairment Market- Competitive Landscape:

The Mild Cognitive Impairment market is moderately competitive. The companies in the market are involved in developing drugs and therapies aimed at managing MCI and related cognitive disorders. Companies like Biogen and Eli Lily are developing treatments for Alzheimer's disease and other neurodegenerative conditions that can overlap with MCI. Companies with strong research and development pipelines are crucial in advancing treatments and diagnostics. Innovation in biomarkers and drug development are key competitive factors.

Recent Developments:

In July 2022, La Roche received FDA approval for the Elecsys Amyloid Plasma panel in the treatment of Alzheimer's disease.

In 2022, Teva Pharmaceuticals launched a generic Revlimid capsule for mild cognitive impairment care.

SCOPE OF THE REPORT

The scope of this report covers the market by its major segments, which include as follows:

GLOBAL MILD COGNITIVE IMPAIRMENT MARKET KEY PLAYERS

• Eli Lilly and Company
• Biogen Inc.
• Roche Holding AG
• Axovant Gene Therapies Ltd.
• GE Healthcare
• Philips Healthcare
• Neurotrack Technologies
• Cogstate Ltd.
• Lumosity Inc.
• Alzheimer's Drug Discovery Foundation (ADDF)
• AstraZeneca
• Novartis International AG
• Takeda Pharmaceutical Company Limited
• Denali Therapeutics Inc.
• HappyNeuron
• Others

GLOBAL MILD COGNITIVE IMPAIRMENT MARKET, BY INDICATION- MARKET ANALYSIS, 2019-2032

• Alzheimer's Disease
• Vascular Dementia
• Lewy Body Dementia
• Parkinson Disease Dementia
• Others

GLOBAL MILD COGNITIVE IMPAIRMENT MARKET, BY DISEASE TYPE- MARKET ANALYSIS, 2019-2032

• Amnestic MCI
• Non-amnestic MCI

GLOBAL MILD COGNITIVE IMPAIRMENT MARKET, BY AGE GROUP- MARKET ANALYSIS, 2019-2032

• Child
• Adult
• Geriatric

GLOBAL MILD COGNITIVE IMPAIRMENT MARKET, BY REGION- MARKET ANALYSIS, 2019-2032

• North America
• The U.S.
• Canada
• Europe
• Germany
• France
• Italy
• Spain
• United Kingdom
• Russia
• Netherlands
• Sweden
• Poland
• Rest of Europe
• Asia Pacific
• India
• China
• South Korea
• Japan
• Australia
• Thailand
• Indonesia
• Philippines
• Rest of APAC
• Latin America
• Brazil
• Mexico
• Argentina
• Colombia
• Rest of LATAM
• The Middle East and Africa
• Saudi Arabia
• United Arab Emirates
• Israel
• Turkey
• Algeria
• Egypt
• Rest of MEA

Table of Contents

1. Mild Cognitive Impairment Market Overview

• 1.1. Study Scope
• 1.2. Market Estimation Years

2. Executive Summary

• 2.1. Market Snippet
  • 2.1.1. Mild Cognitive Impairment Market Snippet by Indication
  • 2.1.2. Mild Cognitive Impairment Market Snippet by Disease Type
  • 2.1.3. Mild Cognitive Impairment Market Snippet by Age Group
  • 2.1.4. Mild Cognitive Impairment Market Snippet by Country
  • 2.1.5. Mild Cognitive Impairment Market Snippet by Region
• 2.2. Competitive Insights

3. Mild Cognitive Impairment Key Market Trends

• 3.1. Mild Cognitive Impairment Market Drivers
  • 3.1.1. Impact Analysis of Market Drivers
• 3.2. Mild Cognitive Impairment Market Restraints
  • 3.2.1. Impact Analysis of Market Restraints
• 3.3. Mild Cognitive Impairment Market Opportunities
• 3.4. Mild Cognitive Impairment Market Future Trends

4. Mild Cognitive Impairment Industry Study

• 4.1. PEST Analysis
• 4.2. Porter's Five Forces Analysis
• 4.3. Growth Prospect Mapping
• 4.4. Regulatory Framework Analysis

5. Mild Cognitive Impairment Market: COVID-19 Impact Analysis

• 5.1. Pre-COVID-19 Impact Analysis
• 5.2. Post-COVID-19 Impact Analysis
  • 5.2.1. Top Performing Segments
  • 5.2.2. Marginal Growth Segments
  • 5.2.3. Top Looser Segments
  • 5.2.4. Marginal Loss Segments

6. Mild Cognitive Impairment Market Landscape

• 6.1. Mild Cognitive Impairment Market Share Analysis, 2023
• 6.2. Breakdown Data, by Key Manufacturer
  • 6.2.1. Established Players' Analysis
  • 6.2.2. Emerging Players' Analysis

7. Mild Cognitive Impairment Market - By Indication

• 7.1. Overview
  • 7.1.1. Segment Share Analysis, By Indication, 2024 & 2032 (%)
  • 7.1.2. Alzheimer's Disease Dementia
  • 7.1.3. Vascular Dementia
  • 7.1.4. Lewy Body Dementia
  • 7.1.5. Parkinson Disease Dementia
  • 7.1.6. Others

8. Mild Cognitive Impairment Market - By Disease Type

• 8.1. Overview
  • 8.1.1. Segment Share Analysis, By Disease Type, 2024 & 2032 (%)
  • 8.1.2. Amnestic MCI
  • 8.1.3. Non-amnestic MCI

9. Mild Cognitive Impairment Market - By Age Group

• 9.1. Overview
  • 9.1.1. Segment Share Analysis, By Age Group, 2024 & 2032 (%)
  • 9.1.2. Child
  • 9.1.3. Adult
  • 9.1.4. Geriatric

10. Mild Cognitive Impairment Market- By Geography

• 10.1. Introduction
  • 10.1.1. Segment Share Analysis, By Geography, 2024 & 2032 (%)
• 10.2. North America
  • 10.2.1. Overview
  • 10.2.2. Mild Cognitive Impairment Key Manufacturers in North America
  • 10.2.3. North America Market Size and Forecast, By Country, 2019 - 2032 (US$ Million)
  • 10.2.4. North America Market Size and Forecast, By Indication, 2019 - 2032 (US$ Million)
  • 10.2.5. North America Market Size and Forecast, By Disease Type, 2019 - 2032 (US$ Million)
  • 10.2.6. North America Market Size and Forecast, By Age Group, 2019 - 2032 (US$ Million)
  • 10.2.7. U.S.
    • 10.2.7.1. Overview
    • 10.2.7.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
    • 10.2.7.3. U.S. Market Size and Forecast, By Indication, 2019 - 2032 (US$ Million)
    • 10.2.7.4. U.S. Market Size and Forecast, By Disease Type, 2019 - 2032 (US$ Million)
    • 10.2.7.5. U.S. Market Size and Forecast, By Age Group, 2019 - 2032 (US$ Million)
  • 10.2.8. Canada
    • 10.2.8.1. Overview
    • 10.2.8.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
    • 10.2.8.3. Canada Market Size and Forecast, By Indication, 2019 - 2032 (US$ Million)
    • 10.2.8.4. Canada Market Size and Forecast, By Disease Type, 2019 - 2032 (US$ Million)
    • 10.2.8.5. Canada Market Size and Forecast, By Age Group, 2019 - 2032 (US$ Million)
• 10.3. Europe
  • 10.3.1. Overview
  • 10.3.2. Mild Cognitive Impairment Key Manufacturers in Europe
  • 10.3.3. Europe Market Size and Forecast, By Country, 2019 - 2032 (US$ Million)
  • 10.3.4. Europe Market Size and Forecast, By Indication, 2019 - 2032 (US$ Million)
  • 10.3.5. Europe Market Size and Forecast, By Disease Type, 2019 - 2032 (US$ Million)
  • 10.3.6. Europe Market Size and Forecast, By Age Group, 2019 - 2032 (US$ Million)
  • 10.3.7. Germany
    • 10.3.7.1. Overview
    • 10.3.7.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
    • 10.3.7.3. Germany Market Size and Forecast, By Indication, 2019 - 2032 (US$ Million)
    • 10.3.7.4. Germany Market Size and Forecast, By Disease Type, 2019 - 2032 (US$ Million)
    • 10.3.7.5. Germany Market Size and Forecast, By Age Group, 2019 - 2032 (US$ Million)
  • 10.3.8. Italy
    • 10.3.8.1. Overview
    • 10.3.8.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
    • 10.3.8.3. Italy Market Size and Forecast, By Indication, 2019 - 2032 (US$ Million)
    • 10.3.8.4. Italy Market Size and Forecast, By Disease Type, 2019 - 2032 (US$ Million)
    • 10.3.8.5. Italy Market Size and Forecast, By Age Group, 2019 - 2032 (US$ Million)
  • 10.3.9. United Kingdom
    • 10.3.9.1. Overview
    • 10.3.9.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
    • 10.3.9.3. United Kingdom Market Size and Forecast, By Indication, 2019 - 2032 (US$ Million)
    • 10.3.9.4. United Kingdom Market Size and Forecast, By Disease Type, 2019 - 2032 (US$ Million)
    • 10.3.9.5. United Kingdom Market Size and Forecast, By Age Group, 2019 - 2032 (US$ Million)
  • 10.3.10. France
    • 10.3.10.1. Overview
    • 10.3.10.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
    • 10.3.10.3. France Market Size and Forecast, By Indication, 2019 - 2032 (US$ Million)
    • 10.3.10.4. France Market Size and Forecast, By Disease Type, 2019 - 2032 (US$ Million)
    • 10.3.10.5. France Market Size and Forecast, By Age Group, 2019 - 2032 (US$ Million)
  • 10.3.11. Russia
    • 10.3.11.1. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
    • 10.3.11.2. Russia Market Size and Forecast, By Indication, 2019 - 2032 (US$ Million)
    • 10.3.11.3. Russia Market Size and Forecast, By Disease Type, 2019 - 2032 (US$ Million)
    • 10.3.11.4. Russia Market Size and Forecast, By Age Group, 2019 - 2032 (US$ Million)
  • 10.3.12. Netherlands
    • 10.3.12.1. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
    • 10.3.12.2. Netherlands Market Size and Forecast, By Indication, 2019 - 2032 (US$ Million)
    • 10.3.12.3. Netherlands Market Size and Forecast, By Disease Type, 2019 - 2032 (US$ Million)
    • 10.3.12.4. Netherlands Market Size and Forecast, By Age Group, 2019 - 2032 (US$ Million)
  • 10.3.13. Sweden
    • 10.3.13.1. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
    • 10.3.13.2. Sweden Market Size and Forecast, By Indication, 2019 - 2032 (US$ Million)
    • 10.3.13.3. Sweden Market Size and Forecast, By Disease Type, 2019 - 2032 (US$ Million)
    • 10.3.13.4. Sweden Market Size and Forecast, By Age Group, 2019 - 2032 (US$ Million)
  • 10.3.14. Poland
    • 10.3.14.1. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
    • 10.3.14.2. Poland Market Size and Forecast, By Indication, 2019 - 2032 (US$ Million)
    • 10.3.14.3. Poland Market Size and Forecast, By Disease Type, 2019 - 2032 (US$ Million)
    • 10.3.14.4. Poland Market Size and Forecast, By Age Group, 2019 - 2032 (US$ Million)
  • 10.3.15. Rest of Europe
    • 10.3.15.1. Overview
    • 10.3.15.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
    • 10.3.15.3. Rest of the Europe Market Size and Forecast, By Indication, 2019 - 2032 (US$ Million)
    • 10.3.15.4. Rest of the Europe Market Size and Forecast, By Disease Type, 2019 - 2032 (US$ Million)
    • 10.3.15.5. Rest of the Europe Market Size and Forecast, By Age Group, 2019 - 2032 (US$ Million)
• 10.4. Asia Pacific (APAC)
  • 10.4.1. Overview
  • 10.4.2. Mild Cognitive Impairment Key Manufacturers in Asia Pacific
  • 10.4.3. Asia Pacific Market Size and Forecast, By Country, 2019 - 2032 (US$ Million)
  • 10.4.4. Asia Pacific Market Size and Forecast, By Indication, 2019 - 2032 (US$ Million)
  • 10.4.5. Asia Pacific Market Size and Forecast, By Disease Type, 2019 - 2032 (US$ Million)
  • 10.4.6. Asia Pacific Market Size and Forecast, By Age Group, 2019 - 2032 (US$ Million)
  • 10.4.7. India
    • 10.4.7.1. Overview
    • 10.4.7.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
    • 10.4.7.3. India Market Size and Forecast, By Indication, 2019 - 2032 (US$ Million)
    • 10.4.7.4. India Market Size and Forecast, By Disease Type, 2019 - 2032 (US$ Million)
    • 10.4.7.5. India Market Size and Forecast, By Age Group, 2019 - 2032 (US$ Million)
  • 10.4.8. China
    • 10.4.8.1. Overview
    • 10.4.8.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
    • 10.4.8.3. China Market Size and Forecast, By Indication, 2019 - 2032 (US$ Million)
    • 10.4.8.4. China Market Size and Forecast, By Disease Type, 2019 - 2032 (US$ Million)
    • 10.4.8.5. China Market Size and Forecast, By Age Group, 2019 - 2032 (US$ Million)
  • 10.4.9. Japan
    • 10.4.9.1. Overview
    • 10.4.9.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
    • 10.4.9.3. Japan Market Size and Forecast, By Indication, 2019 - 2032 (US$ Million)
    • 10.4.9.4. Japan Market Size and Forecast, By Disease Type, 2019 - 2032 (US$ Million)
    • 10.4.9.5. Japan Market Size and Forecast, By Age Group, 2019 - 2032 (US$ Million)
  • 10.4.10. South Korea
    • 10.4.10.1. Overview
    • 10.4.10.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
    • 10.4.10.3. South Korea Market Size and Forecast, By Indication, 2019 - 2032 (US$ Million)
    • 10.4.10.4. South Korea Market Size and Forecast, By Disease Type, 2019 - 2032 (US$ Million)
    • 10.4.10.5. South Korea Market Size and Forecast, By Age Group, 2019 - 2032 (US$ Million)
  • 10.4.11. Australia
    • 10.4.11.1. Overview
    • 10.4.11.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
    • 10.4.11.3. Australia Market Size and Forecast, By Indication, 2019 - 2032 (US$ Million)
    • 10.4.11.4. Australia Market Size and Forecast, By Disease Type, 2019 - 2032 (US$ Million)
    • 10.4.11.5. Australia Market Size and Forecast, By Age Group, 2019 - 2032 (US$ Million)
  • 10.4.12. Thailand
    • 10.4.12.1. Overview
    • 10.4.12.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
    • 10.4.12.3. Thailand Market Size and Forecast, By Indication, 2019 - 2032 (US$ Million)
    • 10.4.12.4. Thailand Market Size and Forecast, By Disease Type, 2019 - 2032 (US$ Million)
    • 10.4.12.5. Thailand Market Size and Forecast, By Age Group, 2019 - 2032 (US$ Million)
  • 10.4.13. Indonesia
    • 10.4.13.1. Overview
    • 10.4.13.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
    • 10.4.13.3. Indonesia Market Size and Forecast, By Indication, 2019 - 2032 (US$ Million)
    • 10.4.13.4. Indonesia Market Size and Forecast, By Disease Type, 2019 - 2032 (US$ Million)
    • 10.4.13.5. Indonesia Market Size and Forecast, By Age Group, 2019 - 2032 (US$ Million)
  • 10.4.14. Philippines
    • 10.4.14.1. Overview
    • 10.4.14.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
    • 10.4.14.3. Philippines Market Size and Forecast, By Indication, 2019 - 2032 (US$ Million)
    • 10.4.14.4. Philippines Market Size and Forecast, By Disease Type, 2019 - 2032 (US$ Million)
    • 10.4.14.5. Philippines Market Size and Forecast, By Age Group, 2019 - 2032 (US$ Million)
  • 10.4.15. Rest of APAC
    • 10.4.15.1. Overview
    • 10.4.15.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
    • 10.4.15.3. Rest of APAC Market Size and Forecast, By Indication, 2019 - 2032 (US$ Million)
    • 10.4.15.4. Rest of APAC Market Size and Forecast, By Disease Type, 2019 - 2032 (US$ Million)
    • 10.4.15.5. Rest of APAC Market Size and Forecast, By Age Group, 2019 - 2032 (US$ Million)
• 10.5. Latin America
  • 10.5.1. Overview
  • 10.5.2. Mild Cognitive Impairment Key Manufacturers in Latin America
  • 10.5.3. Latin America Market Size and Forecast, By Country, 2019 - 2032 (US$ Million)
  • 10.5.4. Latin America Market Size and Forecast, By Indication, 2019 - 2032 (US$ Million)
  • 10.5.5. Latin America Market Size and Forecast, By Disease Type, 2019 - 2032 (US$ Million)
  • 10.5.6. Latin America Market Size and Forecast, By Age Group, 2019 - 2032 (US$ Million)
  • 10.5.7. Brazil
    • 10.5.7.1. Overview
    • 10.5.7.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
    • 10.5.7.3. Brazil Market Size and Forecast, By Indication, 2019 - 2032 (US$ Million)
    • 10.5.7.4. Brazil Market Size and Forecast, By Disease Type, 2019 - 2032 (US$ Million)
    • 10.5.7.5. Brazil Market Size and Forecast, By Age Group, 2019 - 2032 (US$ Million)
  • 10.5.8. Mexico
    • 10.5.8.1. Overview
    • 10.5.8.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
    • 10.5.8.3. Mexico Market Size and Forecast, By Indication, 2019 - 2032 (US$ Million)
    • 10.5.8.4. Mexico Market Size and Forecast, By Disease Type, 2019 - 2032 (US$ Million)
    • 10.5.8.5. Mexico Market Size and Forecast, By Age Group, 2019 - 2032 (US$ Million)
  • 10.5.9. Argentina
    • 10.5.9.1. Overview
    • 10.5.9.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
    • 10.5.9.3. Argentina Market Size and Forecast, By Indication, 2019 - 2032 (US$ Million)
    • 10.5.9.4. Argentina Market Size and Forecast, By Disease Type, 2019 - 2032 (US$ Million)
    • 10.5.9.5. Argentina Market Size and Forecast, By Age Group, 2019 - 2032 (US$ Million)
  • 10.5.10. Colombia
    • 10.5.10.1. Overview
    • 10.5.10.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
    • 10.5.10.3. Colombia Market Size and Forecast, By Indication, 2019 - 2032 (US$ Million)
    • 10.5.10.4. Colombia Market Size and Forecast, By Disease Type, 2019 - 2032 (US$ Million)
    • 10.5.10.5. Colombia Market Size and Forecast, By Age Group, 2019 - 2032 (US$ Million)
  • 10.5.11. Rest of LATAM
    • 10.5.11.1. Overview
    • 10.5.11.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
    • 10.5.11.3. Rest of LATAM Market Size and Forecast, By Indication, 2019 - 2032 (US$ Million)
    • 10.5.11.4. Rest of LATAM Market Size and Forecast, By Disease Type, 2019 - 2032 (US$ Million)
    • 10.5.11.5. Rest of LATAM Market Size and Forecast, By Age Group, 2019 - 2032 (US$ Million)
• 10.6. Middle East and Africa
  • 10.6.1. Overview
  • 10.6.2. Mild Cognitive Impairment Key Manufacturers in Middle East and Africa
  • 10.6.3. Middle East and Africa Market Size and Forecast, By Country, 2019 - 2032 (US$ Million)
  • 10.6.4. Middle East and Africa Market Size and Forecast, By Indication, 2019 - 2032 (US$ Million)
  • 10.6.5. Middle East and Africa Market Size and Forecast, By Disease Type, 2019 - 2032 (US$ Million)
  • 10.6.6. Middle East and Africa Market Size and Forecast, By Age Group, 2019 - 2032 (US$ Million)
  • 10.6.7. Saudi Arabia
    • 10.6.7.1. Overview
    • 10.6.7.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
    • 10.6.7.3. Saudi Arabia Market Size and Forecast, By Indication, 2019 - 2032 (US$ Million)
    • 10.6.7.4. Saudi Arabia Market Size and Forecast, By Disease Type, 2019 - 2032 (US$ Million)
    • 10.6.7.5. Saudi Arabia Market Size and Forecast, By Age Group, 2019 - 2032 (US$ Million)
  • 10.6.8. United Arab Emirates
    • 10.6.8.1. Overview
    • 10.6.8.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
    • 10.6.8.3. United Arab Emirates Market Size and Forecast, By Indication, 2019 - 2032 (US$ Million)
    • 10.6.8.4. United Arab Emirates Market Size and Forecast, By Disease Type, 2019 - 2032 (US$ Million)
    • 10.6.8.5. United Arab Emirates Market Size and Forecast, By Age Group, 2019 - 2032 (US$ Million)
  • 10.6.9. Israel
    • 10.6.9.1. Overview
    • 10.6.9.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
    • 10.6.9.3. Israel Market Size and Forecast, By Indication, 2019 - 2032 (US$ Million)
    • 10.6.9.4. Israel Market Size and Forecast, By Disease Type, 2019 - 2032 (US$ Million)
    • 10.6.9.5. Israel Market Size and Forecast, By Age Group, 2019 - 2032 (US$ Million)
  • 10.6.10. Turkey
    • 10.6.10.1. Overview
    • 10.6.10.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
    • 10.6.10.3. Turkey Market Size and Forecast, By Indication, 2019 - 2032 (US$ Million)
    • 10.6.10.4. Turkey Market Size and Forecast, By Disease Type, 2019 - 2032 (US$ Million)
    • 10.6.10.5. Turkey Market Size and Forecast, By Age Group, 2019 - 2032 (US$ Million)
  • 10.6.11. Algeria
    • 10.6.11.1. Overview
    • 10.6.11.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
    • 10.6.11.3. Algeria Market Size and Forecast, By Indication, 2019 - 2032 (US$ Million)
    • 10.6.11.4. Algeria Market Size and Forecast, By Disease Type, 2019 - 2032 (US$ Million)
    • 10.6.11.5. Algeria Market Size and Forecast, By Age Group, 2019 - 2032 (US$ Million)
  • 10.6.12. Egypt
    • 10.6.12.1. Overview
    • 10.6.12.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
    • 10.6.12.3. Egypt Market Size and Forecast, By Indication, 2019 - 2032 (US$ Million)
    • 10.6.12.4. Egypt Market Size and Forecast, By Disease Type, 2019 - 2032 (US$ Million)
    • 10.6.12.5. Egypt Market Size and Forecast, By Age Group, 2019 - 2032 (US$ Million)
  • 10.6.13. Rest of MEA
    • 10.6.13.1. Overview
    • 10.6.13.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
    • 10.6.13.3. Rest of MEA Market Size and Forecast, By Indication, 2019 - 2032 (US$ Million)
    • 10.6.13.4. Rest of MEA Market Size and Forecast, By Disease Type, 2019 - 2032 (US$ Million)
    • 10.6.13.5. Rest of MEA Market Size and Forecast, By Age Group, 2019 - 2032 (US$ Million)

11. Key Vendor Analysis- Mild Cognitive Impairment Industry

• 11.1. Competitive Dashboard
• 11.2. Company Profiles
  • 11.2.1. Eli Lilly and Company
  • 11.2.2. Biogen Inc.
  • 11.2.3. Roche Holding AG
  • 11.2.4. Axovant Gene Therapies Ltd.
  • 11.2.5. GE Healthcare
  • 11.2.6. Philips Healthcare
  • 11.2.7. Neurotrack Technologies
  • 11.2.8. Cogstate Ltd.
  • 11.2.9. Lumosity Inc.
  • 11.2.10. Alzheimer's Drug Discovery Foundation (ADDF)
  • 11.2.11. AstraZeneca
  • 11.2.12. Novartis International AG
  • 11.2.13. Takeda Pharmaceutical Company Limited
  • 11.2.14. Denali Therapeutics Inc.
  • 11.2.15. HappyNeuron
  • 11.2.16. Others

12. 360 Degree Analyst View

13. Appendix

• 13.1. Research Methodology
• 13.2. References
• 13.3. Abbreviations
• 13.4. Disclaimer
• 13.5. Contact Us